Related Experiment Video
Updated: May 28, 2025
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
Published on: February 16, 2015
Adoptive Cell Therapy for Pediatric Solid Tumors
Amy B Hont1, Catherine M Bollard2
1Center for Cancer and Immunology Research, Children's National Hospital, Washington, D.C. 20010, USA.
Abstract:
Patients with relapsed or refractory pediatric solid tumors have limited therapeutic options with little to no appreciable improvements in outcomes in over two decades. Adoptive cell therapy (ACT) is a promising, targeted option for patients with the potential to minimize acute and long-term toxicities. In this review, we (1) characterize the development and manufacture different ACT approaches used for pediatric solid tumors, and (2) discuss the obstacles when targeting and treating solid tumors. The outcomes of the clinical applications of the various cell therapy products are also reviewed along with the future potential, including novel product development and combination therapies. In sum, this review serves as a comprehensive review of the clinical trial results evaluating the safety, feasibility, and efficacy of novel cell therapy products in the clinic for the treatment of pediatric solid tumors and seeks to provide new insights regarding ACT successes, failures, and challenges to benefit a rapidly expanding immunotherapy field.
Insights
Adoptive cell therapy (ACT) offers a promising new avenue for treating relapsed or refractory pediatric solid tumors, addressing a critical unmet need. This review explores ACT development, challenges, and clinical outcomes for improved pediatric cancer immunotherapy.
Area of Science:
- Oncology
- Immunotherapy
- Pediatric Medicine
Background:
- Relapsed or refractory pediatric solid tumors have limited treatment options with poor outcomes.
- Adoptive cell therapy (ACT) presents a targeted approach with potential for reduced toxicity.
Purpose of the Study:
- To review the development and manufacturing of ACT for pediatric solid tumors.
- To discuss challenges in targeting and treating solid tumors with ACT.
- To evaluate clinical outcomes, future potential, and novel strategies in pediatric ACT.
Main Methods:
- Comprehensive literature review of clinical trials and studies on ACT for pediatric solid tumors.
- Analysis of ACT product development, manufacturing processes, and clinical application data.
- Examination of obstacles and successes in applying ACT to solid tumors.
Main Results:
- ACT approaches are being developed and manufactured for pediatric solid tumors.
- Significant obstacles exist in targeting and treating solid tumors effectively with ACT.
- Clinical outcomes of various ACT products show promise but require further investigation.
Conclusions:
- ACT is a developing immunotherapy with potential for pediatric solid tumors.
- Addressing challenges in ACT development and application is crucial for clinical success.
- Future directions include novel product development and combination therapies for enhanced efficacy.
More Related Videos
10:24Automated Cell Enrichment of Cytomegalovirus-specific T cells for Clinical Applications using the Cytokine-capture System
Published on: October 5, 2015
05:22Intracranial Cannula Implantation for Serial Locoregional Chimeric Antigen Receptor CAR T Cell Infusions in Mice
Published on: February 24, 2023
Related Concept Videos
01:27Tumor Immunotherapy
01:21Stem Cell Therapy for Tissue Regeneration
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
01:22Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...